Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARTHA HERNANDEZ ILLAS

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1972517464
CMS profile
733063
Location
FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$163.00

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $163.00 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $125.00 1
PFIZER INC. $38.00 3

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARTHA HERNANDEZ ILLAS

NPI 1972517464 · CMS profile ID 733063

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $163.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $15.4609/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672777395 CMS
Amgen Inc. $125.0008/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662726285 CMS
PFIZER INC. $6.7503/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672054747 CMS
PFIZER INC. $15.7901/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672016437 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $163.00 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,780,360.32 3
PY2024 Principal investigator $1,857,594.44 9
PY2023 Principal investigator $2,411,538.38 25
PY2022 Recipient $8,492.00 4
PY2022 Principal investigator $6,968,480.90 32
PY2021 Principal investigator $4,588,067.03 55
PY2020 Recipient $1,800.00 2
PY2020 Principal investigator $1,389,670.25 53
PY2019 Principal investigator $5,017,814.30 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $63,091.00 12/24/2019 Non-covered Recipient Entity
QPS MRA LLC
AMG 890_FIH/ SAD No dispute reported 06/30/2026 675778479
Principal investigator 1 Amgen Inc. $10,778.00 12/24/2019 Non-covered Recipient Entity
QPS MRA LLC
AMG 598-Ph 1 Safety; Tolerability; PK and PD of MAD No dispute reported 06/30/2026 675778589
Principal investigator 1 PFIZER INC. $70.00 12/20/2019 Non-covered Recipient Entity
Individual
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671692547
Principal investigator 1 PFIZER INC. $9,752.00 12/04/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671666177
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $739.29 10/28/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RC-P IN HEALTHY ADULT SUBJECTS No dispute reported 06/30/2026 686090161
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $73,966.00 10/25/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RC-P IN HEALTHY ADULT SUBJECTS No dispute reported 06/30/2026 686090151
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $413.35 10/25/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RC-P IN HEALTHY ADULT SUBJECTS No dispute reported 06/30/2026 686090153
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $14,524.00 10/25/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RC-P IN HEALTHY ADULT SUBJECTS No dispute reported 06/30/2026 686090155
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.00 10/25/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RC-P IN HEALTHY ADULT SUBJECTS No dispute reported 06/30/2026 686090157
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,375.00 10/25/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RC-P IN HEALTHY ADULT SUBJECTS No dispute reported 06/30/2026 686090159
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,290.80 10/16/2019 Non-covered Recipient Entity
Qps-mra, Llc (mra Clinical Research)
The Effect of BMS-986165 on the PK of a combined Oral Contraceptive EENET in Healthy Female Subjects No dispute reported 06/30/2026 639758419
Principal investigator 1 PFIZER INC. $1,251.72 10/16/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671666997
Principal investigator 1 PFIZER INC. $23,727.00 10/09/2019 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 3ARM PARALLEL GROUP STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE No dispute reported 06/30/2026 671666179
Principal investigator 1 PFIZER INC. $2,777.04 10/09/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671666271
Principal investigator 1 PFIZER INC. $279.04 10/07/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671684475
Principal investigator 1 Amgen Inc. $27,449.00 09/24/2019 Non-covered Recipient Entity
MRA CLINIC RESEARCH
PMO Self Administration Study ++ No dispute reported 06/30/2026 675788241
Principal investigator 1 PFIZER INC. $11,207.95 09/24/2019 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
AN EXPANDED ACCESS PROTOCOL FOR LORLATINIB FOR TREATMENT OF PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 671658857
Principal investigator 1 PFIZER INC. $1,251.72 09/18/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671666913
Principal investigator 1 PFIZER INC. $2,238.00 09/13/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671666175
Principal investigator 1 PFIZER INC. $111.00 08/16/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671666273
Principal investigator 1 PFIZER INC. $264,622.84 08/06/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671666269
Principal investigator 1 PFIZER INC. $18,814.56 07/17/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671666911
Principal investigator 1 PFIZER INC. $1,287.00 07/03/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671666995
Principal investigator 1 PFIZER INC. $4,285.26 05/22/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671633379
Principal investigator 1 PFIZER INC. $191,208.40 05/08/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671633411
Principal investigator 1 AstraZeneca Pharmaceuticals LP $253,711.64 05/03/2019 Non-covered Recipient Entity
Qps Mra Llc
A Phase 1 Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 684989319
Principal investigator 1 Amgen Inc. $4,070.75 04/30/2019 Non-covered Recipient Entity
QPS MRA,LLC
AMG 598-Ph 1 Safety; Tolerability; PK and PD of MAD No dispute reported 06/30/2026 675790299
Principal investigator 1 PFIZER INC. $199,669.10 04/27/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671633437
Principal investigator 1 Amgen Inc. $10,003.21 04/25/2019 Non-covered Recipient Entity
QPS MRA, LLC
AMG 598-Ph 1 Safety; Tolerability; PK and PD of MAD No dispute reported 06/30/2026 675790289
Principal investigator 1 Amgen Inc. $5,726.47 04/25/2019 Non-covered Recipient Entity
QPS MRA, LLC
AMG 890_FIH/ SAD No dispute reported 06/30/2026 675790295
Principal investigator 1 PFIZER INC. $8,704.47 04/17/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671633377
Principal investigator 1 PFIZER INC. $184,083.40 04/09/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671633409
Principal investigator 1 Eli Lilly and Company $230,847.60 04/08/2019 Non-covered Recipient Entity
QPS MRA LLC
Not supplied No dispute reported 06/30/2026 753910813
Principal investigator 1 PFIZER INC. $3,350.00 04/05/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671633407
Principal investigator 1 Amgen Inc. $70,078.00 03/28/2019 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
AMG 890_FIH/ SAD No dispute reported 06/30/2026 675790255
Principal investigator 1 PFIZER INC. $10,444.00 03/11/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671633375
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,012.50 03/06/2019 Non-covered Recipient Entity
Mra Clinical Research Llc
MEDI4920 CD40L pSS-D5100C00002 Ph1b MAD RA No dispute reported 06/30/2026 684985981
Principal investigator 1 PFIZER INC. $132,057.60 03/05/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671633349
Principal investigator 1 PFIZER INC. $70.00 03/05/2019 Non-covered Recipient Entity
QPSMRA
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671645299
Principal investigator 1 PFIZER INC. $70.00 03/05/2019 Non-covered Recipient Entity
QPSMRA
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671645623
Principal investigator 1 PFIZER INC. $70.00 03/05/2019 Non-covered Recipient Entity
QPSMRA
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671645625
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $247,465.56 03/04/2019 Non-covered Recipient Entity
Mra Clinical Research, Llc
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes No dispute reported 06/30/2026 639758415
Principal investigator 1 Amgen Inc. $15,212.89 03/02/2019 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES CLINICAL RESEARCH
Ph 1 Safety; Tolerability; PK and PD of SAD No dispute reported 06/30/2026 675787885
Principal investigator 1 Amgen Inc. $1,305,600.76 02/27/2019 Non-covered Recipient Entity
QPS MRA LLC
AMG 598-Ph 1 Safety; Tolerability; PK and PD of MAD No dispute reported 06/30/2026 675790273
Principal investigator 1 Amgen Inc. $1,020.00 02/20/2019 Non-covered Recipient Entity
QPS-MRA, LLC-FLORIDA
PMO Self Administration Study ++ No dispute reported 06/30/2026 675790305
Principal investigator 1 PFIZER INC. $133,934.80 02/20/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671620413
Principal investigator 1 PFIZER INC. $1,000.00 02/18/2019 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 3ARM PARALLEL GROUP STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACODYNAMICS OF PF06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE No dispute reported 06/30/2026 671666909
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $562,148.05 02/06/2019 Non-covered Recipient Entity
Mra Clinical Research
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes No dispute reported 06/30/2026 639758417
Principal investigator 1 PFIZER INC. $101,335.38 02/05/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671622093
Principal investigator 1 Amgen Inc. $250.00 01/31/2019 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES CLINICAL RESEARCH
Ph 1 Safety; Tolerability; PK and PD of SAD No dispute reported 06/30/2026 675787887
Principal investigator 1 Amgen Inc. $148,875.21 01/29/2019 Non-covered Recipient Entity
QPS MRA LLC
AMG 890_FIH/ SAD No dispute reported 06/30/2026 675790280
Principal investigator 1 Amgen Inc. $2,827.64 01/28/2019 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
AMG 890_FIH/ SAD No dispute reported 06/30/2026 675790264
Principal investigator 1 Amgen Inc. $613,643.79 01/26/2019 Non-covered Recipient Entity
QPS MRA LLC
Ph 1 Safety; Tolerability; PK and PD of SAD No dispute reported 06/30/2026 675790285
Principal investigator 1 PFIZER INC. $279.04 01/22/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 671620281
Principal investigator 1 Amgen Inc. $9,855.47 01/17/2019 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
AMG 598-Ph 1 Safety; Tolerability; PK and PD of MAD No dispute reported 06/30/2026 675790249
Principal investigator 1 PFIZER INC. $16,910.00 01/11/2019 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 671620149
Principal investigator 1 Amgen Inc. $927.00 01/01/2019 Non-covered Recipient Entity
QPS MRA CLINICAL RESEARCH
AMG 890_FIH/ SAD No dispute reported 06/30/2026 675790269